Clinical trial
Post-Marketing Real World Safety Study of Risankizumab in the United States
NCT04799990 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Post-Marketing Real World Safety Study of Risankizumab in the United States
- Lead sponsor
- AbbVie
- Phase
- Observational
- Overall status
- Withdrawn
- Start date
- June 23, 2021
- Completion date
- March 10, 2022
- Enrollment
- 0 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.